The iShares Biotechnology ETF (IBB) climbed 1.34% on August 22, 2026, closing at $213.63 as the fund extended a broad recovery that has gathered momentum over recent weeks.
Over the past seven days, IBB has advanced 7.78%, reflecting sustained buying pressure across the biotechnology segment. The 30-day gain of 14.22% further underscores the strength of the move, marking a notable shift in performance for the fund over that stretch.
IBB tracks a broad basket of biotechnology equities, giving investors exposure to the sector through a single exchange-traded product. Market capitalization data for the fund was not available as of the reporting date.
The fund's price action over the past month places it among the stronger-performing ETFs in the healthcare space, though the drivers behind individual holdings contributing to the gain were not specified in available data.
